Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway

Molecular Medicine Reports

Volumn 11, Issue 2, 2015, Pages 1516-1522

  Liu, Xiaoyang ^a   Wang, Libo ^a   Chen, Jiajun ^b   Ling, Qi ^c   Wang, Hongfei ^d   Shilin, Li ^a   Li, Liming ^a   Yang, Shuping ^a   Xia, Mingying ^a   Jing, Ling ^a  

^a JILIN UNIVERSITY   (China)

^b JILIN MEDICAL COLLEGE   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

Estrogen receptor ; Liquiritigenin; PI3K AKT mTOR; Temozolomide resistance

Indexed keywords

ALKYLATING AGENT; DACARBAZINE; ESTROGEN RECEPTOR BETA; FLAVANONE DERIVATIVE; LIQUIRITIGENIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE; TEMOZOLOMIDE;

AGONISTS; ANALOGS AND DERIVATIVES; BRAIN TUMOR; CELL SURVIVAL; DRUG EFFECTS; GENETICS; GLIOMA; HUMAN; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DACARBAZINE; ESTROGEN RECEPTOR BETA; FLAVANONES; GLIOMA; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84916241225     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2811     Document Type: Article

References (38)

1. Lacroix M, Abi-Said D, Fourney DR, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95: 190-198, 2001.
2. Kanu OO, Hughes B, Di C, et al: Glioblastoma multiforme oncogenomics and signaling pathways. Clin Med Oncol 3: 39-52, 2009.
3. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
4. Minniti G, Salvati M, Arcella A, et al: Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol 102: 311-316, 2011.
5. Watanabe R, Nakasu Y, Tashiro H, et al: O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma. Brain Tumor Pathol 28: 127-135, 2011.
6. Yin S, Yang J, Lin B, et al: Exome sequencing identifies frequent mutation of MLL2 in non-small cell lung carcinoma from Chinese patients. Sci Rep 4: 6036, 2014.
7. Leung YK, Mak P, Hassan S and Ho SM: Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA 103: 13162-13167, 2006.
8. Burns KA and Korach KS: Estrogen receptors and human disease: an update. Arch Toxicol 86: 1491-1504, 2012.
9. Li LC, Yeh CC, Nojima D and Dahiya R: Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun 275: 682-689, 2000.
10. Roepke TA, Ronnekleiv OK and Kelly MJ: Physiological consequences of membrane-initiated estrogen signaling in the brain. Front Biosci (Landmark Ed) 16: 1560-1573, 2011.
11. Liu MM, Albanese C, Anderson CM, et al: Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277: 24353-24360, 2002.
12. Bailey ST, Shin H, Westerling T, Liu XS and Brown M: Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci USA 109: 18060-18065, 2012.
13. Nilsson S and Gustafsson JA: Estrogen receptors: therapies targeted to receptor subtypes. Clin Pharmacol Ther 89: 44-55, 2011.
14. Paruthiyil S, Cvoro A, Zhao X, et al: Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists. PLoS One 4: e6271, 2009.
15. Suzuki F, Akahira J, Miura I, et al: Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma. Cancer Sci 99: 2365-2372, 2008.
16. Mersereau JE, Levy N, Staub RE, et al: Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol 283: 49-57, 2008.
17. Kim YW, Zhao RJ, Park SJ, et al: Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NF-kappaB-dependent iNOS and proinflammatory cytokines production. Br J Pharmacol 154: 165-173, 2008.
18. Yang EJ, Park GH and Song KS: Neuroprotective effects of liquiritigenin isolated from licorice roots on glutamate-induced apoptosis in hippocampal neuronal cells. Neurotoxicology 39: 114-123, 2013.
19. Zhou M, Higo H and Cai Y: Inhibition of hepatoma 22 tumor by Liquiritigenin. Phytother Res 24: 827-833, 2010.
20. Sareddy GR, Nair BC, Gonugunta VK, et al: Therapeutic significance of estrogen receptor beta agonists in gliomas. Mol Cancer Ther 11: 1174-1182, 2012.
21. Ryu CH, Yoon WS, Park KY, et al: Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. J Biomed Biotechnol 2012: 987495, 2012.
22. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lakins J and Lupu R: Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. Oncol Rep 7: 157-167, 2000.
23. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
24. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006.
25. Yin S, Wang P, Deng W, et al: Dosage compensation on the active X chromosome minimizes transcriptional noise of X-linked genes in mammals. Genome Biol 10: R74, 2009.
26. Yin S, Deng W, Hu L and Kong X: The impact of nucleosome positioning on the organization of replication origins in eukaryotes. Biochem Biophys Res Commun 385: 363-368, 2009.
27. Li W, Winters A, Poteet E, et al: Involvement of estrogen receptor beta5 in the progression of glioma. Brain Res 1503: 97-107, 2013.
28. Lindberg K, Helguero LA, Omoto Y, Gustafsson JA and Haldosen LA: Estrogen receptor beta represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res 13: R43, 2011.
29. Dai C, Zhang B, Liu X, et al: Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology 154: 1247-1259, 2013.
30. Myers MG Jr, Grammer TC, Wang LM, et al: Insulin receptor substrate-1 mediates phosphatidylinositol 3'-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J Biol Chem 269: 28783-28789, 1994.
31. Jiang BH and Liu LZ: Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 11: 63-76, 2008.
32. Deng WJ, Nie S, Dai J, Wu JR and Zeng R: Proteome, phosphoproteome, and hydroxyproteome of liver mitochondria in diabetic rats at early pathogenic stages. Mol Cell Proteomics 9: 100-116, 2010.
33. Gaspar N, Marshall L, Perryman L, et al: MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res 70: 9243-9252, 2010.
34. Toulany M, Lee KJ, Fattah KR, et al: Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Res 10: 945-957, 2012.
35. Chock KL, Allison JM, Shimizu Y and ElShamy WM: BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. Cancer Res 70: 8782-8791, 2010.
36. O'Brien NA, Browne BC, Chow L, et al: Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9: 1489-1502, 2010.
37. Xu J, Zhou JY, Wei WZ and Wu GS: Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 5: e10226, 2010.
38. Wang SI, Puc J, Li J, et al: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57: 4183-4186, 1997.